Category: Impacting News
Impacting News
In This Column Every day thousands of press releases are issued about biotechnology and pharmaceutical firms. Only a few of these press releases have any impact, whether it be positive or negative, on the firms' that are the subject of...
Read More
August 6, 2019
0
Nektar Therapeutics Q2 Results for 2019 Press Release
Nektar Press Release Nektar Therapeutics Results for Q2 of 2019 Nektar Therapeutics (Nasdaq: NKTR ) reported its financial results for the second quarter ended June 30, 2019. Cash and investments in marketable securities at June 30, 2019 were $1.8 billion as compared to $1.9 billion at December 31, 2018. ...
Read More
August 9, 2019
0
Court Upholds Validity of Amgen's Claims Regarding Enbrel
Press Release Amgen Wins Patent Case On Enbrel® (etanercept) Court Upholds Validity of Patent Claims Directed to Enbrel Preliminary Injunction to Remain in Place THOUSAND OAKS, Calif., Aug. 9, 2019 , /PRNewswire/ -- Amgen ( AMGN ) today announced that the U.S. District...
Read More
August 9, 2019
0
A Press Release About Regeneron Product REGN-EB3 Showing Superiority in Preventing Ebola Deaths
Palm Ebola Clinical Trial Stopped Early as Regeneron Product REGN-EB3 Therapy Shows Superiority to ZMapp in Preventing Ebola Deaths TARRYTOWN, N.Y., Aug. 12, 2019,/PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that the Company was informed by study...
Read More
August 13, 2019
0
Moderna's Investigational Zika Vaccine Is Granted FDA Fast Track Designation
From Moderna From the press release we learned that the U.S. Food and Drug Administration ( FDA ) has granted Fast Track designation for Moderna ( MRNA ) investigational Zika vaccine (mRNA-1893) currently being evaluated in a Phase 1...
Read More
August 20, 2019
0
Results From Phase I/IIa Trial of RegenxBio Gene Therapy Product RGX-314
RegenxBio Interim Data from Phase I/IIa Trial of RGX-314 for Wet AMD RegenxBio ( RGNX ) announced interim data from the ongoing Phase I/IIa trial of RGX-314 for the treatment of wet age-related macular degeneration ( wet AMD ). Here...
Read More
October 14, 2019
0
Hepion Pharmaceuticals' Product CRV431 Decreases Fibrosis and Tumor Development in Chronic Liver Disease Models.
Hepion Pharmaceuticals CRV431 Decreased Liver Fibrosis and Tumor Burden in Experimental Models EDISON, NJ / ACCESSWIRE / October 16, 2019 / Hepion Pharmaceuticals, Inc. (NASDAQ: HEPA ), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver...
Read More
October 17, 2019
0
Impacting News
In This Column Every day thousands of press releases are issued about biotechnology and pharmaceutical firms. Only a few of these press releases have any impact, whether it be positive or negative, on the firms' that are the subject of...
Read More
August 6, 2019
0
Cassava Sciences: More Positive News in Alzheimer's Disease
Cassava Sciences: PTI-125 for Alzheimer's Disease Cassava Sciences ( SAVA ) , a clinical-stage biopharmaceutical company focused on Alzheimer’s disease, announced additional clinical data from a Phase 2a study of PTI-125, its investigational drug candidate for Alzheimer’s disease. The new data...
Read More
December 30, 2019
0
Nektar Therapeutics Q2 Results for 2019 Press Release
Nektar Press Release Nektar Therapeutics Results for Q2 of 2019 Nektar Therapeutics (Nasdaq: NKTR ) reported its financial results for the second quarter ended June 30, 2019. Cash and investments in marketable securities at June 30, 2019 were $1.8 billion as compared to $1.9 billion at December 31, 2018. ...
Read More
August 9, 2019
0
Search ProhostBiotech
Popular Links
23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)